1. Scrip
  2. >>Business

BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?

Company Will Earn Nearly $20bn In 2021

 
• By Andrew McConaghie

Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.

Stafford / United Kingdom - November 9 2020: Pfizer BioNTech Covid-19 vaccine concept. Syringe balanced on a fingertip and blurred company logos on the background. Selective focus.
Pfizer and BioNTech now expect to deliver 2.5 billion doses of Comirnaty this year, putting them far ahead of mRNA vaccine rivals Moderna. • Source: Alamy

BioNTech has raised its full-year revenue forecast from its record-breaking COVID-19 vaccine Comirnarty, and now expects to earn €16bn-€17bn ($19.7bn) in 2021.

That is a potential 7% uplift on its BioNTech’s previous forecast of €15.9bn, and in line with the increase its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: top drugs in the first quarter; deal trends at bio; Novo and Lilly’s obesity segmentation plans; Chinese firms at ADA; and five drugs that surpassed sales expectations.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

More from Scrip

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.